Fresh Off the Press in AJOG MFM: Marchand Institute’s New Meta-Analysis on Single- vs. Double-Layer Uterine Closure and Cesarean Scar Outcomes
FOR IMMEDIATE RELEASE
MESA, Ariz. — June 27, 2021
The institute is pleased to announce that ourlatest paper, “Novel oxytocin receptor antagonists for tocolysis: a systematic review and meta-analysis of the available data on the efficacy, safety, and tolerability of retosiban” has been accepted for Publication in Current Medical Research and Opinion. The article can be viewed online at this link, and seen on the United State’s PubMed directory here.
About the Marchand Institute for Minimally Invasive Surgery
The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised using the Cochrane RoB 2 tool. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS.
Media Contact
Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com | (480) 999-0905
Interview requests, expert commentary topics, boilerplate and high-resolution images: Newsroom & Press Kit. Complete publication record with DOIs and PMIDs: Publications database. Methodology: How we run a review.
###
Related posts
